SCHEMBL3542981

SCHEMBL3542981

C=CCOC(=O)c1cc(N)ccc1N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
GAA P10253 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RECQL P46063 1/20 0.46
LMNA P02545 1/20 0.45
HSD17B10 Q99714 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
THRB P10828 1/20 0.45
ALOX15 P16050 1/20 0.45
GFER P55789 1/20 0.45
YWHAG P61981 1/20 0.45
POLB P06746 2/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
CYP3A4 P08684 1/20 0.43
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15487529 0.84 GAA (0.58) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL13009478 0.83 LMNA (0.46) MAPTGAASMN1; SMN2RECQLLMNA
SCHEMBL3541367 0.82 NPC1 (0.67) SMN1; SMN2KMT2ANPC1RAB9APAX8
SCHEMBL31454335 0.80 MAPT (0.56) MAPTGAASMN1; SMN2HSD17B10KMT2A
SCHEMBL422548 0.80 MAPT (0.56) MAPTGAASMN1; SMN2HSD17B10KMT2A
SCHEMBL78016 0.78 MAPT (0.58) MAPTGAASMN1; SMN2HSD17B10KMT2A
SCHEMBL79339 0.76 KDM4E (0.74) MAPTGAASMN1; SMN2LMNAHSD17B10
SCHEMBL2855312 0.76 SMN1; SMN2 (0.60) MAPTGAASMN1; SMN2HSD17B10KMT2A
SCHEMBL5102454 0.76 CYP3A4 (0.64) MAPTGAARECQLHSD17B10KMT2A
SCHEMBL2865872 0.75 MAPT (0.51) MAPTGAASMN1; SMN2RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 MAPT 2115/4885GAA 171/4885SMN1; SMN2 4452/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 MAPT 1986/4885GAA 163/4885SMN1; SMN2 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.